Jun Zhang

Active

Phase I Trial Evaluating the Safety of the Dietary Supplement Honokiol in Early-Stage Resectable Non-Small Cell Lung Cancer

Zhang, J. (PI), Chihara, R. (Key Personnel) & Mathur, S. (Key Personnel)

11/8/24 → …

Project: Clinical Trial

A PHASE 1, OPEN-LABEL, MULTICENTER STUDY OF JANX007 IN SUBJECTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Heyne, K. (Key Personnel), Miles, B. J. (Key Personnel), Satkunasivam, R. (Key Personnel), Singh, M. (Key Personnel) & Zhang, J. (Key Personnel)

10/17/24 → …

Project: Clinical Trial

IMPACT ON SURVIVAL OF FAITH-BASED SPIRITUAL CARE OR PSYCHOTHERAPY COMBINED WITH PALLIATIVE CARE VERSUS PALLIATIVE CARE ALONE IN PATIENTS WITH NON-CURATIVE MALIGNANCIES

Mai, H. P. (PI), Abdelrahim, M. (Key Personnel), Chang, J. C. (Key Personnel), Ganguly, S. (Key Personnel), Heyne, K. (Key Personnel), Mathur, S. (Key Personnel), Niravath, P. A. (Key Personnel), Pingali, S. R. (Key Personnel), Shah, S. (Key Personnel), Sun, K. (Key Personnel), Venta, L. A. (Key Personnel) & Zhang, J. (Key Personnel)

6/19/24 → …

Project: Clinical Trial

Grow It Yourself: The Effect of Hydroponic Vegetable Gardening on Improving Quality of Life in Cancer Patients and Their Caregivers

Zhang, J. (PI) & Satkunasivam, R. (Key Personnel)

7/28/22 → …

Project: Clinical Trial

A Phase II Clinical tRial of neoADjuVant sAsanlimab and stereotaCtiC body radIatioN thErapy as an in situ vaccine for cisplatin-ineligible Muscle Invasive Bladder Cancer (RAD VACCINE MIBC)

Satkunasivam, R. (PI), Butler, E. B. (Key Personnel), Chan, K. S. (Key Personnel), Chen, S.-H. (Key Personnel), Esnaola, N. F. (Key Personnel), Farach, A. M. (Key Personnel), Teh, B. S. (Key Personnel) & Zhang, J. (Key Personnel)

1/20/22 → …

Project: Clinical Trial

RANDOMIZED PHASE II/III TRIAL OF RADIATION WITH CISPLATIN AT 100 MG/M2 EVERY THREE WEEKS VERSUS RADIATION WITH WEEKLY CISPLATIN AT 40 MG/M2 FOR PATIENTS WITH LOCOREGIONALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)

Zhang, J. (PI)

10/27/21 → 10/26/31

Project: Non Profit

INTEGRATION OF IMMUNOTHERAPY INTO ADJUVANT THERAPY FOR RESECTED NSCLC: ALCHEMIST CHEMO-IO (ACCIO)

Bernicker, E. H. (PI) & Zhang, J. (PI)

3/6/20 → 3/5/45

Project: Non Profit

CTSU - IRB SUBMISSIONA Phase III Trial To Evaluate The Efficacy Of The Addition Of Inotuzumab Ozogamicin (A Conjugated Anti-Cd22 Monoclonal Antibody) To Frontline Therapy In Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL.

Abdelrahim, M. (CoI), Bernicker, E. H. (CoI), Chang, J. C. (CoI), Heyne, K. (CoI), Niravath, P. A. (CoI), Singh, M. (CoI) & Zhang, J. (CoI)

3/6/20 → 3/5/45

Project: Non Profit

EA5163/S1709 INSIGNA: A Randomized, Phase III Study of Firstline Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non¿Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature

Bernicker, E. H. (CoI), Darcourt, J. (CoI) & Zhang, J. (CoI)

2/28/19 → 2/27/44

Project: Non Profit

Circulating tumor DNA 5-hydroxymethylcytosine as a novel biomarker for cancers.

Li, Z. (PI), Abdelrahim, M. (Key Personnel), Chang, J. C. (Key Personnel), Darcourt, J. (Key Personnel), Pingali, S. R. (Key Personnel), Sahay, S. (Key Personnel), Shah, S. (Key Personnel), Singh, M. (Key Personnel), Zhang, J. (Key Personnel), Zhou, S. (Key Personnel) & Zu, Y. (Key Personnel)

1/10/19 → …

Project: Clinical Trial

A RANDOMIZED PHASE III DOUBLE BLINDED PLACEBO CONTROLLED TRIAL OFASPIRIN AS ADJUVANT THERAPY FOR HER2 NEGATIVE BREAST CANCER: THE ABCTRIAL

Arentz, C. (PI), Abdelrahim, M. (CoI), Bernicker, E. H. (CoI), Chang, J. C. (CoI), Heyne, K. (CoI), Niravath, P. A. (CoI), Singh, M. (CoI) & Zhang, J. (CoI)

12/8/16 → 12/7/41

Project: Non Profit

Not started

Phase Ib Trial of L-NMMA in Combination With Pembrolizumab in Patients With Melanoma, Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Classical Hodgkin Lymphoma, Urothelial Carcinoma, or Microsatellite Instability-High/Mismatch Repair

Zhang, J. (PI), Heyne, K. (Key Personnel) & Singh, M. (Key Personnel)

Project: Clinical Trial

A Study to Assess the Antitumor Activity and Safety of IMAB362 in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma

Abdelrahim, M. (PI), Chang, J. C. (Key Personnel), Heyne, K. (Key Personnel), Niravath, P. A. (Key Personnel), Singh, M. (Key Personnel) & Zhang, J. (Key Personnel)

Project: Clinical Trial

Durvalumab vs Placebo Following Stereotactic Body Radiation Therapy in Early Stage Non-small Cell Lung Cancer Patients

Zhang, J. (PI), Haque, W. M. (Key Personnel), Heyne, K. (Key Personnel), Shadle, K. M. (Key Personnel) & Singh, M. (Key Personnel)

Project: Clinical Trial

Study of Sasanlimab (PF-06801591) in Combination With Bacillus Calmette-Guerin (BCG) in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (CREST)

Satkunasivam, R. (PI), Singh, M. (Key Personnel) & Zhang, J. (Key Personnel)

Project: Clinical Trial

A Phase 3, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Gemcitabine and Cisplatin in Cisplatin-eligible Participants With Muscle-invasive Bladder Cancer (KEYNOTE-B15 / EV-304)

Satkunasivam, R. (PI), Singh, M. (Key Personnel) & Zhang, J. (Key Personnel)

Project: Clinical Trial

Phase I Trial of Atezolizumab and Interleukin-12 Gene Therapy in Metastatic Non-Small Cell Lung Cancer With Progression on First-Line Immunotherapy With or Without Chemotherapy

Zhang, J. (PI), Chan, E. Y. (Key Personnel), Gibbs, J. M. (Key Personnel), Heyne, K. (Key Personnel), Kim, M. P. (Key Personnel), Rudkovskaia, A. A. (Key Personnel) & Singh, M. (Key Personnel)

Project: Clinical Trial